Klotho Gene Polymorphism in Dialyzed Patients With Hyperphosphatemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-01-31

Study Completion Date

2007-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with chronic kidney disease (CKD) and those with end-stage renal disease (ESRD) undergoing renal replacement therapies show elevated serum phosphate levels which predispose them to cardiovascular calcifications and high risks of death from cardiovascular diseases. However, in certain patients hyperphosphatemia is not related to dialysis insufficiency, excessive daily dietary phosphorus intake or high serum parathyroid hormone (PTH) levels, suggesting that other mechanisms could be involved. Transgenic mice lacking the klotho gene showed a phenotype which resembles that of dialyzed ESRD patients, in the sense that they have hyperphosphatemia, vascular calcifications, and a short lifespan. This study will analyze whether functional polymorphisms or variants in the human klotho gene are associated with hyperphosphatemia in these patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The entire coding region of the klotho gene will be sequenced looking for functional variants and polymorphisms that differentiate two groups of adult dialyzed ESRD patients, matched for age and gender, and with comparable values for dialysis dose and daily protein intake. These two groups consist of one group of 20 adult, dialyzed patients with serum phosphate levels \> 2.50 mM compared to another group of 20 adult, dialyzed ESRD patients with serum phosphate levels \< 1.50 mM. The results of this study will allow to determine whether there is a relationship between extreme hyperphosphatemia and klotho gene polymorphisms in dialysed ESRD patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Disease End Stage Renal Disease Hyperphosphatemia Renal Osteodystrophy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Phosphate Dialysis Klotho Hemodialysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Group 1

* Stable hemodialysis patients for at least 3 months
* Phosphatemia \> 2.5 mM
* Kt/V \> 1.2
* Total weekly phosphate removal \> 75 millimoles

Group 2

* Stable hemodialysis patients for at least 3 months
* Phosphatemia \< 1.5 mM
* Kt/V \> 1.2
* Total weekly phosphate removal \> 25 millimoles

Exclusion Criteria

* Age \> 80 years
* Insufficient dialysis dose (Kt/V \< 1.2)
* Total weekly phosphate removal \< 25 mM
* Problems with vascular access for hemodialysis (central catheter, arteriovenous \[A-V\] fistula dysfunction)
* Methods of dialysis different than the classical hemodialysis (peritoneal, hemofiltration, or hemodiafiltration with or without acetate)
* Intolerance or allergy to ARYLANE M9 dialyzers
* Hypocalcemia \< 2.0 mmol/liter
* Hypophosphatemia \< 0.6 mmol/liter
* Daily protein intake \< 0.6 g/kg/j
* Parathyroidectomy at least 3 months prior to the study
* Evolutive neoplasia with or without secondary lytic bone lesions
* Intestinal malabsorption
* Alcoholism
* Corticotherapy
* Treatment by bisphosphonates, fluor or recombinant PTH
* Malnutrition (body mass index \[BMI\] \< 15)
* Amputation of lower members (\> 10% of total body)
* Prolonged immobilization
* Secondary hyperparathyroidism (PTH \> 1400 pg/ml)
* Vitamin D deficiency (25OHD3 \< 10 ng/ml)

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pablo URENA TORRES, MD

Role: PRINCIPAL_INVESTIGATOR

Clinique de l'Orangerie, France

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinique de l'Orangerie - Service de Néphrologie et Dialyse

Aubervilliers, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Prie D, Beck L, Urena P, Friedlander G. Recent findings in phosphate homeostasis. Curr Opin Nephrol Hypertens. 2005 Jul;14(4):318-24. doi: 10.1097/01.mnh.0000172716.41853.1e.

Reference Type RESULT

PMID: 15930998 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CRC 03161

Identifier Type: -

Identifier Source: secondary_id

P031010